F-star Therapeutics Limited – Trademark Portfolio
Entity Type: 99
F-star Therapeutics Limited holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include MAB2, MAB3, and F-STAR.
Eddeva B920,
Babraham Resarch Campus Cambridge CB22 3AT
Showing of trademarks Trademarks
Trademark Classifications
F-star Therapeutics Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does F-star Therapeutics Limited have?
F-star Therapeutics Limited has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does F-star Therapeutics Limited file in?
F-star Therapeutics Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are F-star Therapeutics Limited's most well-known trademarks?
F-star Therapeutics Limited's registered trademark portfolio includes well-known marks such as MAB2, MAB3, and F-STAR. These are among 3 currently registered trademarks in the portfolio.
What is F-star Therapeutics Limited's trademark registration success rate?
F-star Therapeutics Limited has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.